vs
AVANOS MEDICAL, INC.（AVNS）与Cadre Holdings, Inc.（CDRE）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是Cadre Holdings, Inc.的1.1倍（$180.9M vs $167.2M）。Cadre Holdings, Inc.净利率更高（7.0% vs -0.7%，领先7.7%）。AVANOS MEDICAL, INC.同比增速更快（0.7% vs -5.0%）。AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $18.0M）。过去两年Cadre Holdings, Inc.的营收复合增速更高（10.1% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
Cadre Holdings, Inc.是美国金融科技企业，面向个人及机构客户提供房地产投资项目直投渠道，覆盖纽约等地的商业地产。公司打造的投资平台支持投资者自主选择参与的具体交易项目，且投资门槛远低于全额收购物业所需资金，让不动产投资变得更接近股票交易，获得财经媒体的广泛认可。
AVNS vs CDRE — 直观对比
营收规模更大
AVNS
是对方的1.1倍
$167.2M
营收增速更快
AVNS
高出5.7%
-5.0%
净利率更高
CDRE
高出7.7%
-0.7%
自由现金流更多
AVNS
多$3.3M
$18.0M
两年增速更快
CDRE
近两年复合增速
4.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $167.2M |
| 净利润 | $-1.3M | $11.7M |
| 毛利率 | 47.5% | 43.4% |
| 营业利润率 | 1.4% | 12.2% |
| 净利率 | -0.7% | 7.0% |
| 营收同比 | 0.7% | -5.0% |
| 净利润同比 | 99.7% | -9.6% |
| 每股收益（稀释后） | $-0.02 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSCDRE
| Q4 25 | $180.9M | $167.2M | ||
| Q3 25 | $177.8M | $155.9M | ||
| Q2 25 | $175.0M | $157.1M | ||
| Q1 25 | $167.5M | $130.1M | ||
| Q4 24 | $179.6M | $176.0M | ||
| Q3 24 | $170.4M | $109.4M | ||
| Q2 24 | $171.7M | $144.3M | ||
| Q1 24 | $166.1M | $137.9M |
净利润AVNSCDRE
| Q4 25 | $-1.3M | $11.7M | ||
| Q3 25 | $-1.4M | $10.9M | ||
| Q2 25 | $-76.8M | $12.2M | ||
| Q1 25 | $6.6M | $9.2M | ||
| Q4 24 | $-397.3M | $13.0M | ||
| Q3 24 | $4.3M | $3.7M | ||
| Q2 24 | $1.8M | $12.6M | ||
| Q1 24 | $-900.0K | $6.9M |
毛利率AVNSCDRE
| Q4 25 | 47.5% | 43.4% | ||
| Q3 25 | 48.4% | 42.7% | ||
| Q2 25 | 52.6% | 40.9% | ||
| Q1 25 | 53.6% | 43.1% | ||
| Q4 24 | 54.6% | 43.9% | ||
| Q3 24 | 54.5% | 36.6% | ||
| Q2 24 | 55.7% | 40.6% | ||
| Q1 24 | 57.1% | 41.8% |
营业利润率AVNSCDRE
| Q4 25 | 1.4% | 12.2% | ||
| Q3 25 | 0.1% | 12.0% | ||
| Q2 25 | -42.6% | 9.3% | ||
| Q1 25 | 6.1% | 10.4% | ||
| Q4 24 | -233.0% | 16.7% | ||
| Q3 24 | 7.0% | 5.0% | ||
| Q2 24 | 3.7% | 13.8% | ||
| Q1 24 | 2.4% | 8.7% |
净利率AVNSCDRE
| Q4 25 | -0.7% | 7.0% | ||
| Q3 25 | -0.8% | 7.0% | ||
| Q2 25 | -43.9% | 7.8% | ||
| Q1 25 | 3.9% | 7.1% | ||
| Q4 24 | -221.2% | 7.4% | ||
| Q3 24 | 2.5% | 3.3% | ||
| Q2 24 | 1.0% | 8.7% | ||
| Q1 24 | -0.5% | 5.0% |
每股收益（稀释后）AVNSCDRE
| Q4 25 | $-0.02 | $0.22 | ||
| Q3 25 | $-0.03 | $0.27 | ||
| Q2 25 | $-1.66 | $0.30 | ||
| Q1 25 | $0.14 | $0.23 | ||
| Q4 24 | $-8.64 | $0.32 | ||
| Q3 24 | $0.09 | $0.09 | ||
| Q2 24 | $0.04 | $0.31 | ||
| Q1 24 | $-0.02 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $122.9M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $317.8M |
| 总资产 | $1.1B | $770.0M |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSCDRE
| Q4 25 | $89.8M | $122.9M | ||
| Q3 25 | $70.5M | $150.9M | ||
| Q2 25 | $90.3M | $137.5M | ||
| Q1 25 | $97.0M | $133.4M | ||
| Q4 24 | $107.7M | $124.9M | ||
| Q3 24 | $89.0M | $93.0M | ||
| Q2 24 | $92.2M | $105.9M | ||
| Q1 24 | $75.8M | $87.1M |
总债务AVNSCDRE
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSCDRE
| Q4 25 | $778.2M | $317.8M | ||
| Q3 25 | $778.0M | $340.4M | ||
| Q2 25 | $776.3M | $332.5M | ||
| Q1 25 | $839.4M | $317.6M | ||
| Q4 24 | $828.5M | $311.5M | ||
| Q3 24 | $1.2B | $300.3M | ||
| Q2 24 | $1.2B | $299.4M | ||
| Q1 24 | $1.2B | $270.7M |
总资产AVNSCDRE
| Q4 25 | $1.1B | $770.0M | ||
| Q3 25 | $1.1B | $792.1M | ||
| Q2 25 | $1.0B | $794.4M | ||
| Q1 25 | $1.1B | $656.3M | ||
| Q4 24 | $1.2B | $652.7M | ||
| Q3 24 | $1.7B | $616.6M | ||
| Q2 24 | $1.7B | $620.6M | ||
| Q1 24 | $1.7B | $599.4M |
负债/权益比AVNSCDRE
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $21.3M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $18.0M |
| 自由现金流率自由现金流/营收 | 11.8% | 10.7% |
| 资本支出强度资本支出/营收 | 3.8% | 2.0% |
| 现金转化率经营现金流/净利润 | — | 1.81× |
| 过去12个月自由现金流最近4个季度 | $43.1M | $56.8M |
8季度趋势，按日历期对齐
经营现金流AVNSCDRE
| Q4 25 | $28.2M | $21.3M | ||
| Q3 25 | $14.0M | $22.5M | ||
| Q2 25 | $6.8M | $2.6M | ||
| Q1 25 | $25.7M | $17.4M | ||
| Q4 24 | $57.9M | $23.7M | ||
| Q3 24 | $23.0M | $-5.2M | ||
| Q2 24 | $27.8M | $11.1M | ||
| Q1 24 | $-8.0M | $2.1M |
自由现金流AVNSCDRE
| Q4 25 | $21.3M | $18.0M | ||
| Q3 25 | $7.0M | $21.6M | ||
| Q2 25 | $-4.2M | $1.2M | ||
| Q1 25 | $19.0M | $16.1M | ||
| Q4 24 | $53.1M | $22.4M | ||
| Q3 24 | $20.0M | $-6.2M | ||
| Q2 24 | $21.9M | $9.1M | ||
| Q1 24 | $-12.1M | $794.0K |
自由现金流率AVNSCDRE
| Q4 25 | 11.8% | 10.7% | ||
| Q3 25 | 3.9% | 13.9% | ||
| Q2 25 | -2.4% | 0.7% | ||
| Q1 25 | 11.3% | 12.4% | ||
| Q4 24 | 29.6% | 12.7% | ||
| Q3 24 | 11.7% | -5.7% | ||
| Q2 24 | 12.8% | 6.3% | ||
| Q1 24 | -7.3% | 0.6% |
资本支出强度AVNSCDRE
| Q4 25 | 3.8% | 2.0% | ||
| Q3 25 | 3.9% | 0.5% | ||
| Q2 25 | 6.3% | 0.9% | ||
| Q1 25 | 4.0% | 1.0% | ||
| Q4 24 | 2.7% | 0.7% | ||
| Q3 24 | 1.8% | 0.9% | ||
| Q2 24 | 3.4% | 1.4% | ||
| Q1 24 | 2.5% | 1.0% |
现金转化率AVNSCDRE
| Q4 25 | — | 1.81× | ||
| Q3 25 | — | 2.05× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | 3.89× | 1.88× | ||
| Q4 24 | — | 1.83× | ||
| Q3 24 | 5.35× | -1.43× | ||
| Q2 24 | 15.44× | 0.89× | ||
| Q1 24 | — | 0.31× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
CDRE
| U.s.state And Local Agencies | $72.7M | 43% |
| Other | $48.6M | 29% |
| U.s.Federal Agencies | $31.6M | 19% |
| Commercial | $12.0M | 7% |
